The Oramed transaction could be transformative if executed, providing capital and a high-potential technology platform. However, deteriorating core financials and low cash reserves present near-term risk. Traders should monitor closing of the Oramed deal, execution on new product commercialization, and cash burn in 2026.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 18 $6.72entry
- T+1 · 8mo ago +1.49%α +1.75% · $6.82
- T+5 · 8mo ago −2.83%α −2.11% · $6.53
- T+20 · 7mo ago −0.60%α −6.64% · $6.68
- T+60 · 5mo ago +1.19%α −10.34% · $6.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifeward reported declining revenue and earnings for Q4 and full-year 2025, with Q4 revenue down 33% YoY to $5.1M and adjusted net loss widening. However, the company secured shareholder approval for a transformative strategic transaction with Oramed, gaining access to oral protein delivery technology and up to $47M in funding, which positions it for a potential turnaround. The deal, combined with cost reductions and strategic acquisitions, aims to drive future growth and achieve cash flow positivity.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $5.1M, down 33% YoY from $7.5M in Q4 2024
- Full-year 2025 revenue declined 14% to $22.0M from $25.7M in 2024
- Adjusted gross margin declined to 32.6% in Q4 2025 from 45.5% in Q4 2024
- Adjusted net loss in Q4 2025 increased 27% to $4.2M from $3.3M in Q4 2024
- Shareholder approval obtained for strategic transaction with Oramed, providing up to $47M in funding
- Lifeward to acquire Oramed’s POD™ oral protein delivery technology; Oramed to take up to 49.99% equity stake
- Company acquired powered upper-body exoskeleton tech to expand ReWalk platform
- Reimbursement expanded with Aetna, Humana, and UnitedHealthcare covering ReWalk under Medicare Advantage
- Cash balance was $2.2M as of December 31, 2025, down from $6.7M in 2024
Financial Impact
Revenue declined by $3.7M (-14%) in 2025; adjusted operating loss increased to $15.1M from $16.6M in 2024; transaction with Oramed could bring up to $47M in non-dilutive funding
Risk Factors
- Low cash balance ($2.2M) raises near-term liquidity concerns
- Core revenue and profitability trends are deteriorating despite cost-cutting
- Oramed transaction is not yet closed and subject to final conditions
- High customer concentration and reliance on reimbursement expansions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258091 |
Track record
25 reports on LFWD
7 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +20.27% at T+60 after the Aug 14, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Bearish 6/10 Entry $4.06 Now $3.62 +10.84% settles Nov 20
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $4.06 Now $3.62 −10.84% settles Nov 20
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $6.06 to $5.76 Now $3.62 −40.26% ▼ −4.95% −4.04% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $6.04 to $5.83 Now $3.62 −40.07% ▼ −3.48% −1.49% vs SPY
- Oct 8, 20265w ago 8-K Bearish 5/10 Entry $6.49 to $6.00 Now $3.62 +44.22% ▲ +7.55% +5.58% vs SPY
- Oct 1, 20266w ago 8-K Neutral 2/10 Entry $5.96 to $6.43 Now $3.62 −39.26% ▲ +7.89% +6.58% vs SPY
- Sep 25, 20267w ago DEF 14A Bearish 7/10 Entry $6.92 to $6.67 Now $3.62 +47.69% ▲ +3.61% +4.82% vs SPY
- Aug 14, 202613w ago 8-K Mixed 6/10 No price data
- Aug 14, 202613w ago Press Release Bearish 6/10 Entry $7.45 to $7.32 Now $3.62 +51.41% ▲ +1.75% +0.38% vs SPY
- Aug 11, 202614w ago EFFECT Bearish 7/10 Entry $7.57 to $7.41 Now $3.62 +52.15% ▲ +2.08% +1.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers